A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
Cancer Cell - United States
doi 10.1016/j.ccell.2019.05.010
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2019
Authors
Publisher
Elsevier BV